Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease

Neurology. 2012 Dec 11;79(24):2307-14. doi: 10.1212/WNL.0b013e318278fe32. Epub 2012 Nov 14.

Abstract

Objective: To determine whether evidence of neuronal dysfunction or demise preceded deposition of Lewy pathology in vulnerable neurons in Parkinson disease (PD).

Methods: We examined the extent of nigral dysfunction and degeneration among 63 normal, incidental Lewy body disease (ILBD), and PD cases based on tyrosine hydroxylase (TH) immunoreactivity and neuron densities, respectively. The relationship between these markers and Lewy pathology (LP) burden in the substantia nigra (SN) and Braak PD stage was assessed.

Results: Compared with normal subjects, ILBD cases displayed a significantly higher percentage of TH-negative cells and lower neuronal densities in the SN as early as Braak PD stages 1 and 2, before LP deposition in the nigrostriatal system. ILBD nigral neuron densities were intermediate between normal subjects and PD cases, and TH-negative percentages were higher in ILBD than either normal or PD cases. Furthermore, neuron density and neuronal dysfunction levels remained relatively constant across Braak PD stages in ILBD.

Conclusions: These results suggest that significant neurodegeneration and cellular dysfunction precede LP in the SN, challenging the pathogenic role of LP in PD and the assumption that ILBD always represents preclinical PD.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Cell Count
  • Dopamine / metabolism
  • Female
  • Humans
  • Lewy Bodies / metabolism*
  • Lewy Bodies / pathology
  • Longitudinal Studies
  • Male
  • Nerve Degeneration / metabolism*
  • Nerve Degeneration / pathology
  • Neurons / metabolism*
  • Neurons / pathology
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology
  • Substantia Nigra / metabolism*
  • Substantia Nigra / pathology
  • Tyrosine 3-Monooxygenase / metabolism*

Substances

  • Tyrosine 3-Monooxygenase
  • Dopamine